| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Cyanine 3 Tyramide targets tyrosines on proteins in tissue or cell samples. In tyramide signal amplification, HRP catalyzes the deposition of tyramide molecules onto adjacent tyrosine residues, resulting in localized signal amplification. This allows for the detection of low-abundance targets in tissue and cell samples with enhanced sensitivity.
|
|---|---|
| ln Vitro |
Cyanine 3 Tyramide demonstrates in vitro activity as a fluorescent labeling reagent for signal amplification in immunoassays and nucleic acid in situ hybridization. It provides bright orange-red fluorescence and is widely used for multiplex imaging and detecting low-abundance targets. The compound's activity is dependent on HRP-catalyzed deposition, which amplifies the fluorescent signal.
|
| ln Vivo |
In vivo activity of cyanine 3 tyramide is not applicable, as it is a fluorescent labeling reagent used for in vitro and ex vivo applications. The compound is used for staining tissue sections, cell samples, and nucleic acid probes in research settings.
|
| Enzyme Assay |
In vitro enzyme assays for cyanine 3 tyramide involve its use as a substrate for HRP in tyramide signal amplification. The compound is incubated with HRP-conjugated antibodies or probes, and the HRP catalyzes the deposition of fluorescent tyramide onto nearby tyrosine residues. The amplified signal is then detected using fluorescence microscopy or imaging systems.
|
| Cell Assay |
In vitro cellular assays for cyanine 3 tyramide involve staining cells or tissue sections with HRP-conjugated probes followed by incubation with the fluorescent tyramide substrate. The compound enables the detection of low-abundance antigens or nucleic acid targets with high sensitivity and specificity.
|
| Animal Protocol |
In vivo animal experiments are not applicable to cyanine 3 tyramide, as it is a fluorescent labeling reagent for in vitro and ex vivo applications. The compound is used for staining tissue sections and cell samples obtained from animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data are not applicable to cyanine 3 tyramide as it is a fluorescent labeling reagent, not a therapeutic agent. The compound has a molecular weight of 749.94 and a molecular formula of C39H47N3O8S2. It should be stored under appropriate conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for cyanine 3 tyramide are limited. As a fluorescent dye for research use, comprehensive toxicological studies have not been reported. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
|
| Additional Infomation |
Cyanine 3 Tyramide (Tyramide-Cy3) (CAS#: 174961-75-2) has the molecular formula C39H47N3O8S2 and a molecular weight of 749.94. It is an orange fluorescent dye used for tyramide signal amplification in IHC, ICC, and FISH. The compound is for research use only.
|
| Molecular Formula |
C39H47N3O8S2
|
|---|---|
| Molecular Weight |
749.935788393021
|
| Exact Mass |
749.28
|
| CAS # |
174961-75-2
|
| Related CAS # |
Cyanine 3 Tyramide methyl indole
|
| PubChem CID |
146018932
|
| Appearance |
Brown to black solid powder
|
| LogP |
5.3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
52
|
| Complexity |
1570
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC2=C(C=1)C(C)(C)C(/C=C/C=C1\C(C)(C)C3C=C(C=CC=3N\1CC)S(=O)(=O)O)=[N+]2CCCCCC(NCCC1C=CC(=CC=1)O)=O)(=O)(=O)[O-]
|
| InChi Key |
JPXIOSIRIWBDIC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C39H47N3O8S2/c1-6-41-33-20-18-29(51(45,46)47)25-31(33)38(2,3)35(41)11-10-12-36-39(4,5)32-26-30(52(48,49)50)19-21-34(32)42(36)24-9-7-8-13-37(44)40-23-22-27-14-16-28(43)17-15-27/h10-12,14-21,25-26H,6-9,13,22-24H2,1-5H3,(H3-,40,43,44,45,46,47,48,49,50
|
| Chemical Name |
2-[(E,3E)-3-(1-ethyl-3,3-dimethyl-5-sulfoindol-2-ylidene)prop-1-enyl]-1-[6-[2-(4-hydroxyphenyl)ethylamino]-6-oxohexyl]-3,3-dimethylindol-1-ium-5-sulfonate
|
| Synonyms |
Tyramide-Cy3; Cyanine 3 Tyramide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~20.8 mg/mL (~27.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3334 mL | 6.6672 mL | 13.3344 mL | |
| 5 mM | 0.2667 mL | 1.3334 mL | 2.6669 mL | |
| 10 mM | 0.1333 mL | 0.6667 mL | 1.3334 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
